news
Lower levels of SV2A protein identified as drug target for schizophrenia
Using brain scans, a study has shown that schizophrenia patients have lower levels of the protein SV2A in their brains which presents a drug target.
List view / Grid view
Neurosciences
news
Alzheimer’s vaccine shows promising results in bigenic mice
Researchers have created a new combination vaccine therapy that can induce strong immune responses against tau and Aβ pathologies seen in Alzheimer’s in bigenic mice.
news
Short chain fatty acid supplementation could improve stroke recovery
Researchers have found that supplementing drinking water with short chain fatty acids helped mice to recover from stroke by increasing microglia activity.
news
Origins and potential therapies for a neurodegenerative disorder found
Various potential therapeutic opportunities to treat spinocerebellar ataxia type 7 (SCA7) have been discovered in a new study into the neurodegenerative disorder.
article
A novel approach to unravelling the mysteries of Alzheimer’s
The heterogenous and dynamic nature of protein aggregates makes them a particularly challenging class of structures to study. In this article, Professor Tuomas Knowles and Dr Sean Devenish present a novel approach to studying protein structures that could aid in understanding the complexities of Alzheimer’s disease and identify future therapeutic…
article
The implication of a dysfunctional proteasome regulator in neurodegenerative disease
Disrupted protein homeostasis from PI31 inactivation may initiate the process of neurodegeneration seen in Alzheimer’s, ALS and other similar diseases, says new research.
news
Identifying the right mouse model for Huntington’s disease drug development
Scientists have evaluated mouse models used for developing treatments for mood disorders associated with Huntington's disease and have recommended which have greater potential for success.
article
Targets In-Depth Focus 2019
The articles in this In-Depth Focus explore a novel technique for studying protein aggregation in Alzheimer's research and explain how to maximise the potential of mass spectrometry.
article
Drug Target Review – Issue 4 2019
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
news
New protein function could be key to treatment of drug addiction
Scientists have revealed new findings about the neural circuit involved in the reward stimulus, which plays a major role in drug dependence and psychological disorders.
news
Vasomotion revealed as potential strategy to treat Alzheimer’s
A study has demonstrated that inducing brain vessel pulsations helps to clear substances from the brains of mice, so could be used to stop amyloid-β build up in the development of Alzheimer’s.
news
Direct link shown between inflammasome activation and Alzheimer’s
A new study has demonstrated that NLRP3 inflammasome directly drives tau pathology in neurodegenerative diseases and Alzheimer's disease.
news
Researchers find mutation in CUL3 gene responsible for autism
Scientists have shown that the mutated CUL3 gene, which is involved in the cell’s clearance of proteins, plays a role in the development of autism and schizophrenia in mice.
news
New molecular drivers of Parkinson’s disease uncovered
Molecular drivers of Parkinson's disease have been revealed by scientists who also determined how they impact the functions of genes involved in the condition and the results may point to potential new treatments.
news
ELRIG Drug Discovery 2019: looking back to the future
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
